Losartan Potassium Tablet, Film Coated
Product Images NDC 42708-113

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 42708-113). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Qpharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

42708 113 30

Losartan Potassium Tablet USP, 50 mg, film-coated tablets, packaged as 30 tablets. The label includes directions for use with blanks for dosage, frequency, and duration. Distributed by QPharma, Inc., Cedar Knolls, NJ, with storage instructions to keep at controlled room temperature and keep container tightly closed. The label states it is a sample, not for sale, and for prescription use only (Rx Only).*

FDA Label Image

Losartanaddress2 (Losartanaddress2)

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line graph comparing the percentage of patients with a primary endpoint over 60 study months for Losartan Potassium and Atenolol. The graph shows a trend of increasing events over time, with Losartan Potassium displaying a slightly lower percentage compared to Atenolol. The adjusted risk reduction is noted as 13% with a p-value of 0.021.*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over study months between Losartan Potassium and Atenolol. The graph shows time in months on the x-axis and percentage of patients on the y-axis, indicating a lower percentage for Losartan Potassium compared to Atenolol with an adjusted risk reduction of 25% (p=0.001).*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

Figure 3 presents a forest plot showing primary endpoint events within demographic subgroups comparing Losartan Potassium and Atenolol. It includes event rates (%) and hazard ratios with 95% confidence intervals for primary composite and stroke (fatal/non-fatal) outcomes across age, gender, race, ISH status, diabetes, and history of cardiovascular disease among 8183 patients.*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

Kaplan-Meier plot graph showing the percentage of patients with an event over 48 months comparing Losartan potassium with placebo. The graph illustrates risk reduction and statistical significance (p=0.022) between the two groups.*

FDA Label Image

Losartanstructure (Losartanstructure)

Chemical structure of Losartan Potassium, showing its molecular components, including aromatic rings, chlorine, and potassium ion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.